Accuray Incorporated · NASDAQ:ARAY
Accuray — Q4 FY2022 Earnings Presentation
15 slides from Accuray's earnings presentation, Aug 10, 2022
Slide 1: Q4'FY22 Earnings Call August 10, 2022
Q4’FY22 Earnings Call August 10, 2022
Slide 2: Safe Harbor Statement
Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securiti
Slide 3: Executive Team
Executive Team Suzanne Winter President and CEO Ali Pervaiz Senior Vice President, Chief Financial Officer Sandeep Chalke Senior Vice President, Chief Commercial Officer Jean-Philippe Pignol Senior Vice President, Chief Medical and Technology Officer Jesse Chew Senior Vice President, General Counsel
Slide 4: FY22 Highlights
FY22 Highlights More than 160 new clinical and physics abstracts presented at major conferences worldwide CyberKnife® System gained momentum capitalizing on rapidly growing use of “5 fractions or less” ClearRT™ Imaging won “Best New Technology Solution for Oncology” MedTech Breakthrough Award Introd
Slide 5: Ultra-Hypofractionation is Ready for Prime-Time
Ultra-Hypofractionation is Ready for Prime-Time 20% Adoption0 growing with Phase II-III clinical evidence 70%5 Breast, prostate, lung cancer, and metastases Patient Mix Phase II-III Trials Fast-Forward PACE-B STARS SABR-COMET Adoption 20% HF UHF0 HF: hypofractionation UHF: ultra-hypofractionation Fa
Slide 6: Positive Press Showcasing Impact of the CyberKnife System on Patients' Lives
Positive Press Showcasing Impact of the CyberKnife® System on Patients’ Lives 1 Printed June 30, 2022; https://www.futureofpersonalhealth.com/prostate-and-urological-health/making-prostate-cancer-easier-for-patients-and-their-families/ Coverage in Multiple Media Outlets USA Today Insert1 Owner of Ar
Slide 7: ClearRT: Rapid Adoption of New Standard of Imaging for Radixact CT-Linac
ClearRT™: Rapid Adoption of New Standard of Imaging for Radixact® CT-Linac Helical fan-beam kVCT imaging 115 orders and 73 shipments since introduction 18 months ago MedTech Breakthrough Award: “Best New Oncology Technology Solution” Highlights
Slide 8: FY23 Strategic Pillars
FY23 Strategic Pillars Four Growth Catalysts: Drive Disruptive Innovation Expand Financial Margins Build a More Durable Business Implement Transformational Corporate Strategies 1 2 3 4
Slide 9: Q4'FY22 and FY22 Financials
Q4’FY22 and FY22 Financials Strong financial performance Gross orders $88.3M (22%) $332.3M 2% Revenues $110.0M (1%) $429.9M 8% Product $58.0M 3% $214.7M 22% Service $52.0M (5%) $215.2M (2%) Op. Expenses $41.0M 3% $151.8M 11% R&D $14.6M (5%) $57.7M 10% SG&A $26.4M 9% $94.1M 11% Adj. EBITDA 1 $5.2M (2
Slide 10: FY23 Guidance
FY23 Guidance Takes into account expectations regarding uncertainty and impact from macro environmental climate, FX and China lock downs Revenue Adjusted EBITDA1 $429.9M $22.8M FY23 Guidance Range FY22 Actual $ in millions % = YoY Growth $447M - $455M +4% - 6% $26M - $30M +14% - 32% 1 Adjusted EBITD
Slide 11: In Summary
In Summary Growing Momentum with Record Revenue Strongest Product Portfolio and Pipeline in Company’s History Multiple Growth Catalysts and Global Commercial Execution Focused on Margin Expansion and Free Cash Flow Positioned for Growth Faster Than the Market and Share Gain
Slide 12: Thank you
ACCURAY Thank you Proptotry ond Confienia Propery of Accuroy
Slide 13: GAAP to Adjusted EBITDA Q4 FY2022 and Q4 FY2021 Actual
GAAP to Adjusted EBITDA Q4 FY2022 and Q4 FY2021 Actual Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) $K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for inc
Slide 14: GAAP to Adjusted EBITDA FY2022 and FY2021 Actual
GAAP to Adjusted EBITDA FY2022 and FY2021 Actual Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) $K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income ta
Slide 15: GAAP to Adjusted EBITDA FY2023 – Forward Looking Guidance
GAAP to Adjusted EBITDA FY2023 – Forward Looking Guidance Actual Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) $K GAAP net income (loss) Stock-based compensation Interest expense, net Provisi